事件:707 海外授权辉瑞,12.5 亿美金首付款创中国BD 之最。5 月19日,三生制药发布公告,三生制药将SSGJ-707 除中国内地外的全球开发、生产及商业化权益授予辉瑞,保留中国内地权益并授予辉瑞中国商业化选择权。根据协议,三生制药将获得12.5 亿美元不可退还且不可抵扣的首付款,以及最高可达48 亿美元的开发、监管批准和销售里程碑付款。公司还将根据授权地区的产品销售额收取两位数百分比的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.